PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets will remain closed on 21st October 2019, due to Assembly Elections in Maharashtra.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%
Wed, 20 Jun

PANACEA BIOTECH has announced its results for the quarter ended March 2018. Here is a detailed performance review of the same:

PANACEA BIOTECH Quarterly Financials

No. of Mths
Qtr. Ending
3
Mar-17*
3
Dec-17*
3
Mar-18*
QoQ ChangeYoY Change
Net SalesRs m1,6701,5221,67610.1%0.3%
Other incomeRs m7419127569.8%71.1%
TurnoverRs m1,7441,5411,80217.0%3.3%
ExpensesRs m1,1931,2191,46119.9%22.5%
Gross profitRs m102303215-29.1%110.0%
DepreciationRs m161145138-5.1%-14.3%
InterestRs m2462512572.4%4.5%
Profit before taxRs m-230-74-53
TaxRs m25233239.2%30.8%
Profit after taxRs m-255-97-86
Gross profit margin%6.119.912.8
Effective tax rate%-10.7-31.4-60.7
Net profit margin%-14.6-6.3-4.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 0.3% on a year-on-year (YoY) basis. The expenses were up by 22.5% YoY during the same period.
  • The company's operating profit increased by 110.0% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 12.8% in 4QFY18 as against 6.1% in 4QFY17.
  • Depreciation charges and finance costs declined by 14.3% YoY and 4.5% YoY, respectively.
  • Other income increased by 71.1% YoY during the quarter.
  • Net profit for the quarter declined by 66.5% YoY. Net profit margins during the quarter increased from -14.6% in 4QFY17 to 4.7% in 4QFY18.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 10.1% on a quarter-on-quarter (QoQ) basis. The expenses were up by 19.9% QoQ during the same period.
  • The company's operating profit declined by 29.1% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 12.8% in 4QFY18 as against 19.9% in 3QFY17.
  • Net profit for the quarter declined by 11.9% QoQ, while net profit margins increased from 6.3% in 3QFY17 to 4.7% in 4QFY18.

To see how PANACEA BIOTECH has performed over the last eight quarters, please visit here.

PANACEA BIOTECH Share Price Performance

Over the last one year, PANACEA BIOTECH share price has moved up from Rs 139.3 to Rs 262.1, registering a Gain of Rs 122.8 or around 88.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,264.4 (up 0.3%). Over the last one year it has moved up from 14,083.7 to 14,264.4, a gain of 180.6 points (up 1.3%).

Overall, the S&P BSE SENSEX is up 0.5% over the year.

Current Valuations

At the current price of Rs 262.1, the price to earnings (P/E) ratio of PANACEA BIOTECH stands at NM times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.1 times.

Equitymaster requests your view! Post a comment on "PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%". Click here!

  

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Oct 18, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS